160 related articles for article (PubMed ID: 37496216)
1. [Therapeutic Strategies Targeting HER2 for Gastric Cancer].
Baba K; Boku N
Gan To Kagaku Ryoho; 2023 Jul; 50(7):756-762. PubMed ID: 37496216
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
Ishii T; Shitara K
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
[TBL] [Abstract][Full Text] [Related]
3. Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials.
Lote H; Chau I
Expert Opin Investig Drugs; 2022 Jan; 31(1):59-78. PubMed ID: 35034511
[TBL] [Abstract][Full Text] [Related]
4. An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic.
Kalmuk J; Rinder D; Heltzel C; Lockhart AC
Expert Opin Drug Discov; 2022 May; 17(5):427-436. PubMed ID: 35426752
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
Wang HB; Liao XF; Zhang J
Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
[TBL] [Abstract][Full Text] [Related]
6. HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Grieb BC; Agarwal R
Curr Treat Options Oncol; 2021 Aug; 22(10):88. PubMed ID: 34424404
[TBL] [Abstract][Full Text] [Related]
7. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
Lordick F
Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
[TBL] [Abstract][Full Text] [Related]
9. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
10. HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.
Cytryn SL; Janjigian YY
J Natl Compr Canc Netw; 2023 Apr; 21(4):423-429. PubMed ID: 37015333
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
[TBL] [Abstract][Full Text] [Related]
12. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?
Coutzac C; Funk-Debleds P; Cattey-Javouhey A; Desseigne F; Guibert P; Marolleau P; Rochefort P; de la Fouchardière C
Bull Cancer; 2023 May; 110(5):552-559. PubMed ID: 36229267
[TBL] [Abstract][Full Text] [Related]
13. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
15. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.
Pous A; Notario L; Hierro C; Layos L; Bugés C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511163
[TBL] [Abstract][Full Text] [Related]
16. Current status and future perspectives in HER2 positive advanced gastric cancer.
Roviello G; Catalano M; Iannone LF; Marano L; Brugia M; Rossi G; Aprile G; Antonuzzo L
Clin Transl Oncol; 2022 Jun; 24(6):981-996. PubMed ID: 35091998
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
[TBL] [Abstract][Full Text] [Related]
18. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
[TBL] [Abstract][Full Text] [Related]
19. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives.
Palle J; Rochand A; Pernot S; Gallois C; Taïeb J; Zaanan A
Drugs; 2020 Mar; 80(4):401-415. PubMed ID: 32077003
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
[Next] [New Search]
